That’s early days on that one. We’re trying that out on a number of trials, particularly on some of these more rare disease trials. But the ability for us to access data that we don’t necessarily own, but we have access to, and we can bring together and collate through our systems through our One Search system, which you’ve seen, no doubt, at the Investor Day, and you’ll see some more of this technology at our Investor Day in New York in next month will show you what we’ve been doing and what we’re able to do in terms of bringing these disparate sorts of data together, presenting them in a way that allows us to take actions and take — and make insights into where we find patients for clinical trials. It’s — for us, it’s all about delivering patients into clinical trials and doing that in a really cost effective and a timely basis, and our whole data strategies align towards that.
I know, it’s a bit of a high level answer. We’ll be able to give you a bit more information on this, David, at the Investor Day in New York in a month’s time.
David Windley: Thanks very much. And Brendan, congrats on your career at ICON. Appreciate working with you. Thank you.
Brendan Brennan: Thanks, David. Appreciate that.
Operator: Thank you. We still have a number of questions left. So, in the interest of time, we will be limiting you to one question only. Please standby for your next question. Next question is from Elizabeth Anderson at Evercore ISI. Please go ahead.
Elizabeth Anderson: Hi, guys. Thanks so much for the question. Maybe pivoting off of what Dave just asked, how do we think about the current market for real world evidence? I mean, I think that there’s like some — maybe two phenomenon going on, maybe some sort of cyclical element on it, and also maybe some sort of structural changes as we’ve seen obviously the rise in AI and that kind of thing impacting the market. Could you sort of give us what you sort of view as what’s going on there with your business and sort of where you see the competitive landscape shaking out over the next year or two? Thanks.
Steve Cutler: Elizabeth, yeah, we continue to see real world as an important — really important part of the landscape, and what we need to do — Symphony is a part of that. And we have other sources of real world evidence, as I mentioned, the Veradigm opportunity. So, we see continued interest in there. We see opportunity for growth in there, particularly as we get — as I say, these larger scale trials, I think, the real world is going to be continuing and going to grow significantly. So, there’s a lot there. I don’t think we see any sort of major shift right now, but I think as the obesity drugs really start to be developed, although the new round of them start to be developed, we’ll see increasing — an increasing role for real world evidence and the ability to access it and to take insights from it. So, I could rave on for hours about real world. I won’t do that. But again, you’ll hear more about that at our Investor Day in a couple of weeks.
Elizabeth Anderson: Great. Thanks so much. And congrats, Brendan. It’s been a pleasure.
Brendan Brennan: Thanks, Elizabeth. Cheers.
Operator: Please standby for your next question. Next question is from Jack Meehan at Nephron Research. Please go ahead.
Jack Meehan: Hi. Thanks for squeezing me in. Just one question. In the past in the deck, you’ve also given us the contribution from the number one customer as well. Was just curious how they’re doing? What was their contribution in the quarter? Thanks.
Brendan Brennan: Yeah. Hi, Jack. It’s Brendan here. It was similar to last quarter in that kind of 8% to 9% range. I think, we wanted to move away from being overly focused on one customer. I think, I made the point earlier in the call that we are seeing a more diversified company as we go forward and it aligns again with our quarterly filings with the SEC, that we would care about one to five. That’s the way we’ll be showing that as we go forward.
Operator: Please standby for your next question. Next question is from Luke Sergott at Barclays. Please go ahead.
Luke Sergott: Great, thanks. Can you talk about the — like, the pass throughs that — the trends that you’re seeing here in the current quarter and the elevated booking — your bookings that you had for this quarter, anything to step up there? We’re just trying to find anything, I guess, to pick at or find issue with?
Brendan Brennan: No. No luck there, Luke. Brendan here. Obviously, that — we had a very solid quarter in terms of bookings, but that wasn’t based on elevated pass-throughs or anything like that. We had a very solid direct fee book-to-bill as well. Not dissimilar. So, no, nothing there to particularly get you guys worried about. It was a very solid quarter across the organization and very much in terms of direct fee also.
Luke Sergott: Great, thanks. I vote for Winley to throw his hat in the ring, Brendan.
Brendan Brennan: For the gig? Yeah. Yeah.
Kate Haven: Of course. Of course. Put them in.
Steve Cutler: We need to talk, Luke.
Brendan Brennan: I won’t describe you Steve’s face right now, Luke, anyway.
Operator: Please stand by for your next question. This comes from Jack Wallace at Guggenheim Partners. Please go ahead.
Unidentified Analyst: Hi. This is Mitch on for Jack. Thanks for taking my question. Most of mine have been asked and answered, but maybe just one on therapeutic mix. Is there anything to note in regards to changes in mix in the first quarter or in the pipeline? Thanks.
Steve Cutler: Mitch, no, not really. We continue with a good 40% of our work in the oncology space, and then the rest of them are sort of between 10% and 15%. Anti-infectors, vaccines, CNS, cardiovascular, it might mix. It might go up and down a little bit on a trial if a big trial comes in. But really, still the most — some more than 50%, but about 40% works in oncology and rare disease. And so that tends to dominate our portfolio.
Operator: Please standby for your final question. And this comes from Jailendra Singh at Truist Securities. Please go ahead.
Jailendra Singh: Thank you. And thanks for squeezing me in. And congrats Brendan as well. Just wanted to ask about BIOSECURE Act and what you guys are hearing from your global pharma customers. And even this act passes, if you see this act having any implications for the CRO industry and global CRO players like ICON?
